A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

NCT03999658 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sorrento Therapeutics filed for chapter 11 bankruptcy.

Conditions

Peripheral T Cell Lymphoma
Diffuse Large B Cell Lymphoma
Biliary Tract Cancer
Extranodal NK T Cell Lymphoma, Nasal

Interventions

BIOLOGICAL: STI-3031

Sponsor

Sorrento Therapeutics, Inc.